Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40 percent. This is a 8.16 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $301.665 million which beat the analyst consensus estimate of $279.198 million by 8.05 percent. This is a 48.26 percent increase over sales of $203.471 million the same period last year.